Cambridge Investment Research Advisors, Inc. Viking Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 13,419 shares of VKTX stock, worth $344,197. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,419
Previous 42,389
68.34%
Holding current value
$344,197
Previous $2.68 Million
79.88%
% of portfolio
0.0%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding VKTX
# of Institutions
468Shares Held
65.9MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$261 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$155 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$126 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$66.5 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$55.3 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $1.97B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...